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Generating induced pluripotent stem cells (iPSCs)
requires massive epigenome reorganization. It is
unclear whether reprogramming of female human
cells reactivates the inactive X chromosome (Xi), as
in mouse. Here we establish that human (h)iPSCs
derived from several female fibroblasts under stan-
dard culture conditions carry an Xi. Despite the lack
of reactivation, the Xi undergoes defined chromatin
changes, and expansion of hiPSCs can lead to partial
loss of XIST RNA. These results indicate that hiPSCs
are epigenetically dynamic and do not display a pris-
tine state of X inactivationwith two active Xs as found
in some female human embryonic stem cell lines.
Furthermore, whereas fibroblasts are mosaic for
the Xi, hiPSCs are clonal. This nonrandom pattern
of X chromosome inactivation in female hiPSCs,
which is maintained upon differentiation, has critical
implications for clinical applications and disease
modeling, and could be exploited for a unique form
of gene therapy for X-linked diseases.
INTRODUCTION
Induced pluripotent stem cells (iPSCs) have generated enor-
mous interest because they provide a source of patient-specific
cells for regenerative medicine. iPSCs are obtained from differ-
entiated mouse or human cells by forced expression of a few
transcription factors related to pluripotency, most commonly
consisting of Oct4, Sox2, c-Myc, and Klf4 (Takahashi et al.,
2007; Takahashi and Yamanaka, 2006; Yu et al., 2007). It is
recognized that iPSCs are functionally and molecularly very
similar to embryonic stem cells (ESCs) (Maherali et al., 2007;
Okita et al., 2007; Wernig et al., 2007). Hence, mouse (m)iPSCs,
like mESCs, can differentiate into all three germ layers in vitro or
in the teratoma assay in vivo, and even give rise to animals
entirely derived from these cells (Boland et al., 2009; Zhao
et al., 2009). Because of ethical concerns, it is impossible to
judge the extent of reprogramming of human (h)iPSCs by more
stringent assays of pluripotency such as chimerism or tetraploid
complementation, highlighting the importance of indirectCellmethods to assay the character and quality of these cells. Here
we focus on the epigenetic status of the somatically silenced
X chromosome in female hiPSCs to better understand the equiv-
alency of hESCs and hiPSCs and to compare the human and
mouse reprogramming processes.
In female cells, one of the two X chromosomes is transcription-
ally silenced through a process referred to as X chromosome
inactivation (XCI). XCI, best studied in the mouse system, is
developmentally regulated and initiated when female mESCs
or their in vivo equivalents of the blastocyst are induced to differ-
entiate (Payer and Lee, 2008). In the embryo, XCI is random such
that approximately half of the cells inactivate the maternally
inherited X chromosome and the other half the paternal X. Initia-
tion of XCI is absolutely dependent on the large noncoding RNA
Xist encoded on the X chromosome (Marahrens et al., 1997;
Wutz and Jaenisch, 2000). Upon induction of differentiation,
Xist is exclusively upregulated the future inactive X chromosome
(Xi) and spreads along the chromosome in cis to initiate silencing.
Silencing of the X is accompanied by exclusion of Polymerase II
and activating chromatin marks followed by sequential accumu-
lation of repressive chromatin marks (Payer and Lee, 2008).
Coating of the Xi by Xist RNA and the heterochromatic state
are then maintained for the lifetime of the organism. Intriguingly,
upon reprogramming of somatic cells from female mice, the Xi is
reactivated, such that miPSCs, just like mESCs, carry two active
X chromosomes (Xas) that are competent for random XCI upon
induction of differentiation (Maherali et al., 2007). Reactivation
of the Xi is a late event in the reprogramming process, mirroring
the activation kinetics of endogenous pluripotency genes such
as Nanog and Oct4 (Stadtfeld et al., 2008), although the exact
relationship between Xi reactivation and establishment of the
pluripotency transcription network remains unclear. Thus, two
Xas appear to be a critical determinant of the pluripotent state
of mESCs/iPSCs.
Unlike mESCs, female hESC lines display a highly variable
epigenetic status of the X chromosome, even differing for the
same hESC line at different passages, under varying culture
conditions, or among subclones (Adewumi et al., 2007; Dhara
and Benvenisty, 2004; Hall et al., 2008; Hoffman et al., 2005;
Lengner et al., 2010; Shen et al., 2008; Silva et al., 2008).
Although a few female hESC lines can, at least partially, carry
two Xas and undergo random XCI upon differentiation, many
lines display complete XCI in the undifferentiated state with an
XIST RNA-coated, heterochromatic Xi. Other hESC lines contain
an Xi that lacks XIST expression and XIST RNA-dependentStem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 329
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Figure 1. Establishment of Female hiPSCs via Lenti- and Retroviral Polycistronic Reprogramming Cassettes
(A) Schematic representation of reprogramming experiments performed with the STEMCCA lentiviral vector. This vector encodes the mouse reprogramming
factors in the order of Oct4 (O), Klf4 (K), Sox2 (S), and cMyc (C). The four starting female human fibroblast lines are listed.
(B) As in (A) for the MIP-retroviral reprogramming approach with fibroblast line NHDF17914. The MIP-vector encodes the human reprogramming factors in the
indicated order followed by GFP (G).
(C) Phase-contrast image of a representative STEMCCA-hiPSC colony.
(D) TRA1-60 (green) and NANOG (red) immunostaining of STEMCCA-hiPSC line E. Nuclei were detected with Dapi (blue).
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Female Human iPSCs Retain an Inactive X Chromosomerepressive chromatin marks and do not reactivate XIST upon
differentiation (Silva et al., 2008). It remains unclear whether
hiPSCs display the variable states of XCI described for hESCs,
and whether reactivation of the Xi seen in mouse reprogramming
is recapitulated during the generation of hiPSCs. Resolving these
questions will be critical for our understanding of the epigenetic
equivalency between hESCs and hiPSCs and could impact on
the use of hiPSCs in disease modeling and clinical applications.
To address the XCI status upon human cell reprogramming, we
analyzed XIST and X-linked gene expression as well as chro-
matin composition in a large number of female hiPSC lines
derived from four independent female fibroblast populations
with two viral reprogramming strategies.
RESULTS
Derivation of Female hiPSCs via Two Different Viral
Approaches
To gain insight into the epigenetic status of the X chromosomes
upon reprogramming of female human somatic cells, we reprog-
rammed four normal fibroblast lines, including one from an
embryonic source and three from females of varying ages
(Table S1 available online) via a single polycistronic lentiviral
vector encoding Oct4, Klf4, Sox2, and c-Myc under control of
the constitutive EF1a promoter (termed STEMCCA-vector)
(Sommer et al., 2009). According to standard protocols, fibro-
blast cultures were split onto feeders 5 days after viral transduc-
tion and bFGF-containing hESC media was added on day 6
(Figure 1A). Dramatic changes in morphology were evident
only a few days later and colonies with ESC-like morphology
were clonally expanded into stable cell lines as early as 14 days
postinfection and will subsequently be referred to as STEMCCA-
hiPSC lines. In addition, we generated hiPSC lines from one of
the adult female fibroblast populations by using a new polycis-
tronic retroviral vector encoding human OCT4, SOX2, KLF4,
c-MYC, as well as GFP, separated by 2A sequences and a puro-
mycin resistance gene after an IRES element (called MIP-vector,
Figure 1B). The only deviation from the prior reprogramming
protocol was a brief addition of puromycin to the culture media
to select successfully transduced fibroblasts. Colonies arose
as early as 21 days postinfection and lines are referred to as
MIP-hiPSCs (Figure 1B).
Multiple STEMCCA- and MIP-hiPSC lines (total of 30) were
stably expanded and demonstrated typical characteristics of
human pluripotent stem cells (Table S1). In addition to their
hESC-like morphology (Figure 1C), they were strongly positive
for NANOG and TRA1-60 in immunostainings (Figure 1D;(E) Graph summarizing real-time PCR data for transcript levels of endogenously
GAPDH expression.
(F) Bisulfite sequencing of promoter regions of NANOG and OCT4 in indicated c
(G) Analysis of MIP-based GFP expression at different steps of the reprogrammin
before puromycin selection demonstrating approximately 9% infection efficiency
all cells express GFP at day 5 of reprogramming upon puromycin selection. Resu
the FACS analysis of MIP-hiPSC line 2 in the bottom row.
(H) Real-time PCR for ectopic expression from the MIP- (top) or STEMCCA- (botto
sion.
(I) Teratoma formation with differentiation into all three germ layers in three repre
See Figure S1 for additional data.
CellTable S1) and re-expressed the endogenous copies of
OCT4 and SOX2 and other key pluripotency genes (Figure 1E),
indicating successful reactivation of crucial pluripotency
markers, which was corroborated by bisulfite sequencing
experiments that demonstrated the demethylation of the
NANOG and OCT4 promoter regions (Figure 1F). As expected
from these results, we observed silencing of the polycistronic
MIP- and STEMCCA-expression cassettes in hiPSC clones
compared to infected fibroblasts (Figures 1G and 1H) and
residual ectopic expression progressively decreased upon
continued passaging of the lines (Figure S1A). All analyzed hiPSC
lines were karyotypically normal (Figure S1B) and had a genome-
wide expression profile highly similar to that of hESCs as they
clustered together closely with hESCs and apart from their
fibroblast origin (Figure S1C). In directed in vitro differentiation
assays, these cells generated neural progenitors (ectoderm),
fibroblasts (mesoderm), and hepatocytes (endoderm), which
were confirmed by immunostainings and genome-wide expres-
sion (Figures S1D and S1E and data not shown), and differenti-
ated in vivo into teratomas with discernable elements of all
embryonic germ layers (Figure 1I). Thus, our STEMCCA- and
MIP-hiPSC lines met the most stringent criteria for pluripotency,
an important prerequisite for the subsequent analysis of the
XCI status.
XIST RNA Coats One X Chromosome in Undifferentiated
Female hiPSC Lines
XISTRNA, the keymolecule of XCI, is highly transcribed from the
Xi and coats the chromosome in female fibroblasts, which can be
visualized by RNA fluorescence in situ hybridization (FISH) as
a large nuclear area enriched for the RNA signal (Figure 2A). To
determine the XCI status upon successful reprogramming, we
first characterized various STEMCCA-hiPSC lines for XIST
RNA expression and localization. A single XIST RNA-coated
chromosome occurred in around 88% of NANOG-positive cells
in each hiPSC line (Figures 2B and 2C; Table S1), closely resem-
bling the pattern found in the starting female fibroblast popula-
tions. This result was confirmed with MIP-hiPSC lines (Figures
2D and 2E). XIST RNA is released from the Xi during mitosis,
potentially explaining the lack of RNA enrichment in some of
the NANOG-positive cells (Clemson et al., 1996). High-level
expression of XIST in all female lines was confirmed by expres-
sion arrays and, as expected, not found in male control cells
(Figure S2). The presence of an XIST RNA-coated X chromo-
some suggested that female hiPSCs carry an Xi, independent
of the fibroblast source or the type of virus used to overexpress
the reprogramming factors.expressed pluripotency genes in indicated cell lines. All values are relative to
ell lines.
g process. FACS analysis of GFP levels in MIP-retrovirally infected fibroblasts
. Phase-contrast and GFP fluorescence images to the right indicate that almost
lting hiPSCs do not express GFP as shown in the GFP fluorescence image and
m) reprogramming cassettes in indicated cell lines, relative to GAPDH expres-
sentative hiPSC lines.
Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 331
A%
 o
f N
A
N
O
G
+ 
ce
lls
w
ith
 X
IS
T 
R
N
A 
cl
ou
d
0
20
40
60
80
100
16 19 241061
NHDF 3975
IMR90
NHDF 17622
NHDF 17914
Donor Fibroblast Lines
Dapi/XIST RNA
B C
Dapi/XIST RNA
4 4 passage #6 6 4 4
Dapi/XIST RNA/
NANOG
E G
6 6
D E
Dapi/XIST RNA NANOG Merge
0
20
40
60
80
100
1 2 3 4 5
3 3passage # 3 3 3
%
 o
f N
A
N
O
G
+ 
ce
lls
w
ith
 X
IS
T 
R
N
A 
cl
ou
d
passage #
line
line
Figure 2. Female hiPSCs Carry a Single XIST RNA-Coated Chromosome
(A) FISH for XIST RNA (green) in the Dapi-stained fibroblast line NHDF 17430. The accumulation of XIST RNA on the Xi can be seen as focal nuclear enrichment of
the RNA signal.
(B) FISH for XIST RNA (green) in the STEMCCA-hiPSC line E, merged with Dapi in the left image, and overlaid with an immunostaining for NANOG (red) in the right
image.
(C) The graph depicts the percentage of NANOG-positive cells with a single Xi-like accumulation of XISTRNA for various STEMCCA-hiPSC lines. Fibroblast origin
is marked with gray scale indicators and passage of hiPSCs is indicated.
(D) As in (B) with NANOG in green and XIST RNA in red for MIP-hiPSC line 1. Scale bar denotes 10 mm.
(E) As in (C) for various MIP-hiPSC lines. See Figure S2 for additional data.
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hiPSCs
It is possible that XIST RNA expression and its coating of the
chromosome are uncoupled from XCI in hiPSCs. To determine
the expression state of the XIST RNA-associated chromosome,
we carried out RNA FISH for the X-linked geneATRX in bothMIP-
and STEMCCA-hiPSC lines, which allows the detection of
nascent transcripts at the site of transcription. The majority of
cells displayed a single nuclear spot of ATRX transcripts in
NANOG-positive cells, which was never associated with the
XIST RNA-coated X chromosome, and biallelic expression of
ATRXwas consistently not observed (Figures 3A–3F). The exclu-
sive expression of XIST and ATRX indicated that the XIST RNA-
coated chromosome is transcriptionally inactive in hiPSCs.
However, to ensure that expression of the ATRX gene, which is
located close to XIST on the X, reflects that of the entire X chro-
mosome, we performed XIST RNA FISH in combination with
immunostainings for two active histone modifications, acetyla-
tion of lysine (K) 18 and methylation of K4 of histone H3, both
of which should be excluded from the entire X chromosome
area, when it is inactive. Both histone marks were depleted
from the area occupied by XIST RNA (Figures 3G and 3H) and
similar experiments demonstrated exclusion of Polymerase II
from the XIST RNA-coated region (data not shown), confirming
that the XIST RNA-coated chromosome is transcriptionally inac-
tive in faithfully reprogrammed hiPSCs.
Previously, it had been found that the single Xa in female and
male somatic cells is dosage compensated, doubling its tran-
scription to achieve an X to autosome expression ratio of 1 for
both sexes (Gupta et al., 2006; Nguyen and Disteche, 2006). In332 Cell Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Infemale mESCs, the X:A expression ratio is enhanced to 1.5
because of the presence of two Xas (Lin et al., 2007). Based
on our analysis, the calculated X:A ratio in human fibroblasts
and female hiPSC lines is close to 1 (Figure S3), consistent
with the presence of the Xi in our female hiPSCs. However, it still
needs to be determined whether hESCs with two Xas would
have an increased X:A ratio.
XCI Is Nonrandom in Female hiPSCs
The presence of an Xi in female hiPSCs raised the question of
which of the two X chromosomes is inactive in these cell lines.
During mouse and human embryonic development, XCI results
in silencing of one X chromosome in every female somatic cell,
but the selection of paternal versus maternal X chromosome
for inactivation is an independent and random event in each
cell (Payer and Lee, 2008). Therefore, cells in the fibroblast pop-
ulation are thought to be mosaic for the Xi (Figure 4A, left). To
test whether hiPSCs also have a random pattern of XCI (Fig-
ure 4A, II) or are clonal, with one of the two X chromosomes
exclusively being inactive (Figure 4A, I), we identified single
nucleotide polymorphisms (SNPs) that led to differential restric-
tion enzyme digest patterns between the two X chromosomes,
by sequencing of relevant genomic regions in one female
fibroblast line (NHDF17914). SNPs were selected within exons
of XIST and ATRX, and the 30UTR of PDHA1, encoded on the
distal tip of the X chromosome about 53 Mb away from XIST,
to address the allele-specific expression status along the X
(Figure S4A). As expected, random XCI was found in the starting
fibroblast population by detection of transcripts from both alleles
of XIST, PDHA1, and ATRX (Figures 4B–4D; Figure S4B).c.
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Figure 3. The XIST RNA-Coated Chromosome Is Inactive in Female hiPSCs
(A) NANOG immunostaining (red) combined with RNA FISH forATRX nascent transcripts (green) in the Dapi-stained STEMCCA-hiPSC line 19. A pinpoint of ATRX
marks the site of nascent transcription and occurs from only one X chromosome.
(B) The graph depicts the quantification of NANOG-positive cells with monoallelic, biallelic, or no ATRX expression for various STEMCCA-hiPSC lines at the indi-
cated passage. Fibroblast origin is given as in Figure 2C.
(C) As in (A) for MIP-hiPSC line 1.
(D) As in (B) for various MIP-hiPSC lines.
(E) FISH for XIST RNA (red) and ATRX transcripts (green) in STEMCCA-hiPSC line G at passage 8 with Dapi staining the nucleus. The XIST RNA cloud signal does
not overlap with the single ATRX signal.
(F) As in (E) for MIP-hiPSC line 5 at passage 3 with XIST RNA in green and ATRX transcripts in red.
(G) Immunostaining for H3K18ac (green) and FISH for XIST RNA (red) in STEMCCA-hiPSC line E at passage 8. Exclusion of the histone mark can be seen at the
site of XIST RNA accumulation and was found in 96% of cells in the population indicating silencing of the entire XIST RNA-coated X in hiPSCs. Scale bar repre-
sents 5 mm.
(H) As in (G), except that Xi exclusion of H3K4 me3 was analyzed. Exclusion of this histone mark was found in 92% of hiPSCs. See Figure S3 for additional data.
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ATRX were detected in each NHDF17914-derived hiPSC line
(Figures 4B–4D; Figure S4B), indicating that all cells in a given
hiPSC line exclusively express one of the two X chromosomes.
Interestingly, different hiPSC lines derived from the same fibro-
blast population can differ in which X chromosome displays inac-
tivation because they express opposite XIST, ATRX, and PDHA1
alleles (Figures 4B–4D; compare STEMCCA-hiPSC lines inG andCellE; Figure S4B for different MIP-hiPSC lines). This mutually exclu-
sive, nonrandom pattern of XCI in hiPSCs obtained from one
fibroblast population (Figures 4A–4I) suggests that each hiPSC
line is derived from a single fibroblast in the donor cell population
without intermittent reactivation of theXi and that theXCI status in
a hiPSC line reflects that of the starting fibroblast.
To further substantiate that the Xi does not reactivate during
human cell reprogramming, we immortalized NHDF17914Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 333
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Figure 4. Nonrandom XCI in Female hiPSC Lines
(A) Schematic representation of random XCI in fibroblasts and potential XCI states in female hiPSC lines.
(B) Analysis of allele-specific expression of XIST via restriction enzyme-sensitive SNPs. RNA from NHDF17914 fibroblasts and STEMCCA-hiPSC lines E and G
(passages 8–9) derived from this fibroblast population was reverse transcribed and two regions of XIST surrounding different SNPs were amplified by PCR and
analyzed with and without the respective restriction digest as indicated. SNPs were chosen such that the PCR product derived from the two X alleles are differ-
entially cleaved as indicated. Note that fibroblasts express both XIST alleles, whereas hiPSC line G exclusively expresses one and line E the other allele.
(C) As in (B) except for allele-specific expression of ATRX.
(D) As in (B) except for allele-specific expression of PDHA1.
(E) A subclone of NHDF17914 fibroblasts obtained upon delivery of a lentiviral shRNA targeting p53 was reprogrammed with the STEMCCA approach and allele-
specific expression of PDHA1 determined at different times of the reprogramming process via the same assay as in (D). In this assay, this fibroblast subclone
expresses only allele 2 and does not reactivate allele 1 during reprogramming.
(F) As in (B) but allele-specific expression of XIST was analyzed upon differentiation of STEMCCA hiPSC lines E and G into neural precursors (NPCs), indicating
that nonrandom XCI is preserved upon differentiation.
(G) As in (F) except for allele-specific expression of ATRX in hiPSC-derived NPCs. See Figure S4 for additional information.
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Female Human iPSCs Retain an Inactive X Chromosomefibroblasts via a constitutive knockdown of p53 and isolated a
clonal fibroblast line that expressed only the X carrying allele 2
of PDHA1. We then asked whether allele 1 of PDHA1, located on
the Xi, becomes expressed during the reprogramming process
(Figure 4E). Although the sensitivity of the SNP-based expres-
sion assay may be limited, transcripts from allele 1 were not
detected, further supporting the notion that the Xi does not reac-
tivate during the reprogramming process.
Nonrandom XCI Is Preserved upon Differentiation
of hiPSC Lines
Because XCI, at least in the mouse system, is tightly linked to
differentiation, we next tested whether the nonrandom pattern
of XCI found in undifferentiated hiPSCs is maintained upon
induction of differentiation. Two female STEMCCA-hiPSC lines,
differing in which X chromosome they express, were differenti-
ated into neural precursors as confirmed by immunostaining
(Figures S1D and S1E). By using our SNP-based method of
detection for allelic expression, we found that hiPSC-derived
neural precursors displayed the same nonrandom pattern of
XCI that is found in the undifferentiated state (Figures 4F and
4G). Similarly, we observed conservation of the nonrandom
pattern of XCI when hiPSCs were differentiated into fibroblasts
(Figure S4C). Thus, differentiation of hiPSCs does not alter the
XCI pattern present in the undifferentiated state.
Changes in Xi Chromatin Structure during Human Cell
Reprogramming
In mouse, XCI during development is associated with a loss of
active chromatin modifications and the sequential accumulation
of repressive chromatin marks (Payer and Lee, 2008). Accord-
ingly, the chromatin state of the Xi differs at various stages of
the XCI process. For example, Polycomb Group (PcG) proteins
of the Polycomb Repressive Complex 2 (PRC2) complex accu-
mulate immediately upon initiation of XCI to mediate the enrich-
ment of histone H3K27 trimethylation on the Xi (Plath et al., 2003;
Silva et al., 2003). The accumulation of PRC2 on the Xi is lost
upon establishment of the inactive state when analyzed by
immunostaining, even though high-level H3K27 trimethylation
persists on the Xi for the life of the organism. Here, we assayed
the status of the PRC2 subunit EZH2 on the Xi in fibroblasts and
hiPSCs by immunostaining to determine whether this mark of the
Xi changes during reprogramming. As expected, 93% of fibro-
blasts carried an Xi enrichment of H3K27 trimethylation, but
only around 2% of these Xis accumulated EZH2 (Figure 5A).
Intriguingly, various MIP- and STEMCCA-hiPSC lines consis-
tently displayed an Xi enrichment of EZH2 in an average of
88% of NANOG-positive cells (Figures 5B and 5C). A similar
proportion of cells displayed XIST RNA coating in Figure 1 in
agreement with the notion that EZH2 recruitment to the Xi is
dependent on XIST RNA. Interestingly, the enrichment of EZH2
on the Xi occurs only after NANOG is upregulated during the
reprogramming process (data not shown). Therefore, reprog-
ramming appears to return the Xi chromatin to a state resembling
the initiation phase of XCI.
Other chromatinmarks were also different between fibroblasts
and hiPSCs but were much less dramatically affected, with 43%
versus 89% of fibroblasts and hiPSCs, respectively, displaying
an Xi-like accumulation of macroH2A1 (Figure S5A), and 3%Cellversus 10% cells carrying strong H4K20 monomethylation
(Figure S5B). In contrast, the exclusion of activating histone
marks occurred to the same degree between fibroblasts and
hiPSC lines (Figures 3G and 3H and data not shown). Collectively
these data indicate that certain aspects of the Xi chromatin state
are changed during reprogramming from a pattern typically seen
in the maintenance phase of XCI to one that is found only when
XCI is initiated during development.
Enrichment of EZH2 was the most pronounced change in Xi
chromatin structure during reprogramming. To begin to address
the underlying mechanism for this transition in chromatin
composition, we first determined the expression level of EZH2
and, in accordance with data in the mouse system, found higher
transcript levels of EZH2 in hiPSCs than fibroblasts (Figure 5D),
which is also reflected in higher protein levels (data not shown).
To test whether differential global EZH2 levels represent
a possible explanation for the Xi enrichment of this protein in
hiPSCs, we altered its expression levels in fibroblasts and
hiPSCs, respectively. Knockdown of EZH2 by RNAi in hiPSCs
(Figure 5E) led to a visible reduction of EZH2 protein levels in
around 50% of the cells under maintenance of the Xi-like enrich-
ment as determined by immunostaining (Figure 5F). Conversely,
raising EZH2 levels in fibroblast by overexpression of an EZH2-
GFP fusion protein did not lead to Xi-like accumulation of the
protein (Figure 5G). Together, these data suggest that differential
EZH2 protein levels between the different developmental stages
are not a simple explanation for the divergence in EZH2 Xi
enrichment between fibroblasts and hiPSCs.
Prolonged Passaging Affects Xi Characteristics
Our results indicated that female hiPSCs, when first analyzed
at around passages 4–10, consistently carried an XIST RNA-
coated Xi. We reasoned that the Xi could be maintained but
lose XIST expression, as has been described for some female
hESCs upon extended culturing, or still reactivate at later
passage or under altered culture conditions. To test this idea,
we expanded several hiPSC lines in bFGF-containing media
on mouse fibroblast support cells to passage 22 and reanalyzed
Xi markers. In some hiPSC lines, XIST RNA expression and
EZH2 enrichment on the Xi were maintained in the majority of
cells (data not shown). However, we also had lines in which
extended culturing led to changes in the XCI status with a loss
of the nuclear XIST RNA enrichment in most cells (Figure 6A)
and dramatic reduction in XIST transcript levels (Figure S2,
see STEMCCA-hiPSCs E and G at passage 22). RNA FISH
demonstrated that ATRX continued to be expressed from
only one X chromosome in XIST-negative hiPSC colonies (Fig-
ure 6A), and our SNP-based expression assay indicated the
maintenance of monoallelic expression for PDHA1 (Figure 6B),
suggesting that the inactive state of the X is preserved even
in the absence of XIST RNA coating. Cytogenetic analysis
demonstrated the presence of two X chromosomes, allowing
us to exclude the loss of one of the two X chromosomes in
these cultures as a possible explanation for XIST loss (Fig-
ure S1B). In agreement with this finding, X chromosome
painting in combination with immunostaining for RNA poly-
merase II confirmed that one of the two X chromosomes is
depleted for the basic transcriptional machinery (Figure 6C).
Even though our data indicate the presence of an Xi, it remainsStem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 335
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Figure 5. Characterization of Xi Chromatin in Female hiPSCs
(A) Immunostaining for EZH2 (green) and H3K27me3 (red) in NHDF17914 fibroblasts; nuclei were detected with Dapi. The proportion of cells with an Xi-like accu-
mulation for H3K27me3 and EZH2 are given.
(B) Immunostaining for EZH2 (gray, from far-red channel), NANOG (green), and FISH for XIST RNA (red) in STEMCCA-hiPSC line G at passage 8.
(C) Proportion of NANOG-positive cells with an Xi-like accumulation of EZH2 for various MIP and STEMCCA-hiPSC lines at around passages 4–8. See Figure S5
for additional data.
(D) Real-time PCR data for EZH2 transcript levels in given cell types, normalized to GAPDH.
(E) Real-time PCR data for EZH2 transcript levels in early passage STEMCCA-hiPSCs upon treatment with scrambled siRNA controls (siControl) or siRNAs
targeting EZH2 (siEZH2), normalized to GAPDH.
(F) Immunostaining forEZH2 inanearly-passageSTEMCCA-hiPSC lineupontransfectionofcontrolorEZH2siRNAs.Cells aremosaic fordepletionofEZH2andarrow-
heads point to EZH2 Xi enrichment in cells with clear EZH2 knockdown. However, it should be noted that the Xi enrichment appears smaller than that normally seen.
(G) Immunostaining for histone H3K27me3 (red) and EZH2 (far-red, pseudocolored in cyan) in fibroblasts 2 days after transfection of a GFP-EZH2 overexpression
plasmid. The zoom in suggests that higher global levels of EZH2 in fibroblasts do not lead to Xi enrichment of EZH2.
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(A) RNA FISH for XIST (green) andATRX (red) transcripts in STEMCCA-iPS line G at passage 16. At this passage, many cells without XISTRNA clouds were found.
Note that ATRX continues to be expressed from only one chromosome. At around passage 22, this hiPSC line lost XIST RNA expression and coating in almost all
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(C) X chromosome paint (green) in STEMCCA-hiPSC lines G at passage 22 to detect the presence of two X chromosomes. The combination of the X paint with
RNA polymerase II immunostaining (red) illustrated that one of the two X chromosomes labeled with arrowheads is completely excluded from RNA polymerase II
staining indicative of an Xi.
(D) Bisulfite sequencing of promoter region of XIST in indicated cell lines. Half of the clones were completely methylated in female fibroblasts and early passage
STEMCCA-hiPSC in agreement with the notion that XIST is silenced on the Xa and actively expressed from the Xi. Completemethylationwas found in STEMCCA-
hiPSC line G at passage 22, which has lost XIST expression, and our H9 hESC culture, which also lacks XIST expression but contains an Xi (data not shown).
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Female Human iPSCs Retain an Inactive X Chromosomepossible that loss of XIST may result in partial derepression of
the silent chromosomes as previously suggested for hESCs
with an Xi that lacks XIST coating (Lengner et al., 2010; Shen
et al., 2008).
Bisulfite sequencing of the XIST promoter region implicated
DNA methylation in the silencing of XIST as shown by the fact
that cells lacking XIST expression from the Xi exhibited complete
methylation, whereas cells expressing XIST from the Xi, like
female fibroblasts or early-passage hiPSCs, were characterized
by demethylation of 50% of the clones (Figure 6D). In agreement
with the XIST dependence of certain chromatin marks, we found
that loss of XISTRNA from the Xi in hiPSCs was accompanied by
the loss of the Xi accumulation of EZH2, macroH2A, and
H4K20me1 in immunostainings (data not shown), suggesting
that XIST-independent chromatin marks must keep the X silent
in cells that lack XIST expression. Collectively, these data
suggest that adaptation to culture conditions can affect the
epigenetic state of the Xi in hiPSCs.CellDevelopment of Female Duchenne Muscular
Dystrophy-hiPSC Lines
Because the finding of nonrandom XCI in female hiPSCs could
be exploited for studies of X-linked diseases (see Discussion),
we finally generated hiPSC lines from heterozygous females
that are carriers of an X-linked disease. Duchenne Muscular
Dystrophy (DMD) is an X-linked recessive disease that arises
from mutations in the DYSTROPHIN gene (Hoffman et al.,
1987). DMD occurs at an incidence of 1 in 3500 live male births
and is the most common and severe muscular disorder in child-
hood. To test whether we can generate hiPSCs expressing either
the wild-type or mutant form of DYSTROPHIN from a female
carrier of the disease (Figure 7A), fibroblasts from a 47-year-
old female that is clinically unaffected but heterozygous for
a deletion of exons 46–50 of the DYSTROPHIN gene (EX46-
50DEL; DMD fibroblast line 158) were reprogrammed via the
STEMCCA approach. For control purposes, we also generated
hiPSCs from fibroblasts from the 13-year-old son that is clinicallyStem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 337
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Figure 7. Female DMD hiPSCs Exclusively Express the Mutant or Wild-Type Allele of DYSTROPHIN
(A) Schematic representation of the expected result in the reprogramming experiment with male and female DMD fibroblasts via in the STEMCCA approach.
(B) TRA1-60 (green) immunostaining and FISH for XIST RNA (red) in a representative female DMD-hiPSC line at passage 3. Nuclei were detected with Dapi (blue).
(C) Graph summarizing real-time PCR data for transcript levels of endogenously expressed pluripotency genes in indicated cell lines, relative to GAPDH expres-
sion.
(D) As in (C) for ectopic expression from the STEMCCA cassette and endogenous levels of SOX2.
(E) Bisulfite sequencing of promoter regions of NANOG and OCT4 in female DMD fibroblasts and the descendant hiPSC clone 158b.
(F) PCR analysis of DMDexpression in female andmale DMD-hiPSC clones. Thewild-type andmutant alleles ofDYSTROPHIN can easily be distinguished by size
(1411 bp versus 716 bp). As expected, the male line (162) expressed only the mutant allele and only one of the two DYSTROPHIN alleles was transcribed in each
female hiPSC line.
(G) SNP-based analysis of allele-specific expression of ATRX in female DMD fibroblasts, two descendant hiPSC clones (158b and 158e), and one male DMD
hiPSC line (162f). Both ATRX alleles are present in fibroblasts, but only one can be detected in each female hiPSC line.
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blast line 162). An initial characterization of stably expanded
male and female DMD-hiPSC clones, referred to as 162 and
158, respectively (six female and four male lines; Table S1),
demonstrated typical characteristics of pluripotent stem cells:
morphology similar to hESCs (data not shown); expression of
TRA1-60 and other pluripotency genes (Figures 7B and 7C);
silencing of the ectopic STEMCCA reprogramming cassette
(Figure 7D); and demethylation of the OCT4 and NANOG
promoter regions (Figure 7E); all suggestive of complete
reprogramming. As expected, all female DMD-hiPSC lines also
carried an XIST-RNA-coated X chromosome, confirming our
original results (Figure 7B).
To test whether female hiPSCs expressed either the wild-type
or mutant form of DYSTROPHIN, we took advantage of the facts
that the gene is expressed at very low levels in human pluripotent338 Cell Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Incells and that the two forms can be distinguished by PCR frag-
ment length polymorphisms. We found that the female DMD-
hiPSC line 158b expressed the wild-type but not the mutant
form of DYSTROPHIN, whereas only the mutant allele could be
detected in another line (158e), which, as expected, was also
present in the disease-derived male hiPSC line 162f
(Figure 7F). These data suggested that hiPSC lines 158b and
158e express different X chromosomes, a result that could be
extended to the other female DMD-hiPSC lines (data not
shown). This conclusion was further tested with our SNP-based
assay for allele-specific expression of ATRX, which showed
that female DMD-hiPSC lines expressed only one of the two
ATRX alleles present in fibroblasts (Figure 7G and data not
shown for additional lines). Importantly, female DMD-hiPSC lines
that expressed different DYSTROPHIN forms also expressed
opposite alleles of ATRX, confirming that mutually exclusive Xc.
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Female Human iPSCs Retain an Inactive X Chromosomechromosomes are expressed among various DMD-hiPSC lines.
We conclude that female hiPSCs expressing only the mutant
allele of an X-linked gene can be generated from a heterozygous
female carrier of an X-linked mutation as a result of the clonality
of the reprogramming process and lack of Xi reactivation.
DISCUSSION
In this study, we provide the first extensive characterization of
the XCI status upon reprogramming of female human somatic
cells. We discovered that completely reprogrammed hiPSCs,
derived under standard bFGF culture conditions, carry an Xi
with XIST RNA coating and classic markers of Xi heterochro-
matin. This outcome is consistent among all hiPSC lines gener-
ated here, irrespective of the age of the person from which the
starting fibroblast population was obtained or the particular viral
reprogramming approach applied. Female hiPSC lines display
nonrandom XCI and different lines obtained from the same fibro-
blast culture differ in which of the two X chromosomes they
express. This mutually exclusive, nonrandom pattern of XCI
among hiPSC lines is consistent with the notion that the Xi
does not reactivate during reprogramming of human somatic
cells and that a single cell from the mosaic fibroblast population
that has silenced either the maternally or the paternally inherited
X chromosome gives rise to the reprogramming event (model
proposed in Figure 4A). Upon expansion in culture, female hiPSC
cells are prone to lose XIST expression, probably through meth-
ylation of its promoter, similar to what has been observed with
female hESCs (Hall et al., 2008; Lengner et al., 2010; Shen
et al., 2008; Silva et al., 2008). The absence of XIST RNA coating
leads to the loss of XIST-dependent chromatin marks but not to
the reactivation of the Xi, although we can currently not exclude
partial derepression of the X chromosome accompanying XIST
loss. A better understanding of the cause of this dynamic epige-
netic behavior of hiPSCs will be important, because the XCI
status may reflect the global epigenetic status of human plurip-
otent cells.
In contrast to our findings with mouse reprogramming, which
showed that female miPSCs consistently carry two Xas, our
current analysis did not reveal any sign of complete reactivation
of the somatically silenced X chromosome in hiPSCs, indicating
that the reversal of XCI is not required for human cell reprogram-
ming. Even though mouse reprogramming leads to the reactiva-
tion of the Xi in a late step of the reprogramming process,
it remains to be determined how the heterochromatin of the Xi
is transformed into euchromatin, and whether this process is
essential for the establishment of the pluripotent state in mouse.
Addressing these questions will help to reveal why human cell
reprogramming does not include the reactivation of the Xi.
However, one possible explanation for the XCI differences of
mouse and human reprogramming could be that the epiblast
progenitor cells of the human blastocyst, in contrast to those
of the mouse blastocyst, do not carry two Xas. The X chromo-
some activation status in human blastocysts has not been firmly
established and direct evidence that, as in mouse, both X chro-
mosomes are transcriptionally active in epiblast cells of the blas-
tocyst is still lacking (van den Berg et al., 2009). Thus, it is
possible that the Xi/Xa pattern found in hiPSCs and most hESCs
reflects the state of the X chromosomes found at this develop-Cellmental stage in vivo, which would suggest a dramatic difference
in the developmental regulation of X chromosome activity
between mouse and human embryos. However, a recent report
described the derivation of hESCswith two Xas from blastocysts
under physiological oxygen conditions (Lengner et al., 2010).
The same study nicely demonstrated that hESCs with two Xas
initiate XCI in response to different kinds of cellular stress,
including exposure to atmospheric oxygen levels, possibly ex-
plaining why most hESC lines cultured in labs to date carry an
Xi. Thus, it appears likely that the epiblast progenitor cells of
the human blastocyst have two Xas and that cellular stress
during derivation and maintenance of hESCs leads to progres-
sive perturbations of this epigenetic state and precocious XCI
in the undifferentiated state (Lengner et al., 2010; Silva et al.,
2008). Importantly, once XCI is initiated in hESCs, hypoxic condi-
tions or antioxidant treatments do not appear to enable
reactivation of the Xi in hESCs (Lengner et al., 2010). Thus, we
currently favor the idea that the inability to reproduce the XaXa
pattern in hiPSCs may be explained by the irreversibility of exist-
ing XCI in standard hESC culture conditions. In agreement with
this conclusion, the addition of several antioxidants to estab-
lished hiPSC lines or during the reprogramming process or
reprogramming experiments under hypoxic conditions did not
result in reactivation the Xi in our preliminary experiments (data
not shown). However, theoretically the failure to completely
reprogram our hiPSCs to the hESC state with two Xas remains
possible. It also remains possible that the presence of the re-
programming cassette could affect the XCI status seen in
hiPSCs, even though ectopic expression is strongly downregu-
lated in our hiPSC lines.
Another explanation for XCI differences between the human
and mouse reprogramming may be that hESCs/iPSCs represent
a developmentally more advanced pluripotent state than
mESCs/iPSCs. Accordingly, hESCs/iPSCs are thought to be in
a primed pluripotent state, whereas mESCs represent the naive
pluripotent state (Nichols and Smith, 2009). Differences in culture
conditions for these two pluripotent stages with hESCs/iPSCs
requiring bFGF signaling and mESC/iPSCs depending on the
LIF/STAT pathway may be tightly associated with their different
XCI states. Intriguingly, a more hESC-like stem cell population
has been derived from the mouse postimplantation epiblast
(EpiSCs) that displays an Xi/Xa pattern with Xist RNA coating
(Guo et al., 2009; Nichols and Smith, 2009). Conversely, it has
also been suggested recently that a more naive pluripotent state
with two Xas can be established in hESCs by histone deacety-
lase inhibition (Ware et al., 2009) or constant overexpression of
KLF4 in combination with small molecule cocktail that supports
mESC growth (Hanna et al., 2010). Additional studies are needed
to reveal the origin of the epigenetic differences found between
mouse and human ESCs/iPSCs and the epigenetic state of the
X chromosome may serve a valuable tool for elucidating these
differences.
hiPSCs have garnered great interest in part because disease-
specific hiPSCs, which theoretically can form any cell type of the
human body, offer an unprecedented opportunity to examine
disease states and may form the basis for drug development
approaches. To date, hiPSCs have been generated from
patients with a variety of genetic diseases including ALS, SMA,
Parkinson’s disease, Huntington’s disease, juvenile-onset, type 1Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inc. 339
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Ebert et al., 2009; Park et al., 2008), and should also be invalu-
able for studies of X-linked diseases (Agarwal et al., 2010;
Urbach et al., 2010). Our finding that female hiPSCs exhibit
nonrandom XCI should have implications for the use of female
hiPSCswith X-linkedmutations in clinical applications or disease
studies. Devastating X-linked genetic diseases include for
example fragile X syndrome (mutation in FMR1), a-thalassemia
(ATRX), Rett Syndrome (MECP2), Coffin-Lowry Syndrome
(RSK2), DMD, Lesch-Nyhan syndrome (HPRT), and Wiskott-
Aldrich Syndrome (WASP). Furthermore, approximately 11% of
X-linked genes are implicated in mental retardation (Gecz
et al., 2009). It has long been recognized that XCI has important
consequences for the clinical phenotype of X-linked diseases
between the two sexes. The cellular mosaicism with respect to
XCI is often advantageous for women’s health, ameliorating
the deleterious effects of X-linked mutations and leading to
less severe manifestations of the disease compared to males.
However, there are X-linked mutations that are often lethal in
males in utero and severely affect females (for example Rett
Syndrome and Incontinentia Pigmenti) or that manifest in
females even in the heterozygous case (X-linked Adrenoleuko-
dystrophy). Our finding that each female hiPSC line, in contrast
to the starting fibroblast population, is clonal for X-linked gene
expression leads to the prediction that hiPSC lines derived
from females with an X-linked disorder will express either the X
carrying the mutant or the normal allele, which we were able to
confirm with our female DMD-hiPSC derived from a heterozy-
gous carrier. For studies of X-linked diseases with female
hiPSCs, one therefore needs to carefully analyze which X chro-
mosome is expressed. One could argue that hiPSC lines from
females with X-linked disorders thereby represent the perfect
pair of control (expressing the normal allele) and experimental
(expressing the mutant allele) cell types for investigation of the
disease phenotype. More importantly, we propose that one
could be able to exploit the nonrandom XCI feature of female
hiPSCs for a form of gene therapy, because a mosaic population
of cells expressing the mutant and wild-type allele from the
female patient can be turned into a pluripotent, isogenic cell pop-
ulation that carries the mutant allele on the Xi in all cells and thus
solely expresses the normal form of the gene.EXPERIMENTAL PROCEDURES
Reprogramming Methods, hiPSC Culture, and Differentiation
NHDF and IMR90 fibroblast cell lines were obtained from Lonza and ATCC,
respectively. DMD-fibroblasts GM05158 and GM05162 were obtained from
the NIGMS Human Genetic Cell Repository from Coriell. All cells were grown
and procedures performed under a protocol approved by the Chancellor’s
Animal Research Committee (ARC) and Embryonic Stem Cell Research
Oversight (ESCRO) committee at UCLA. For STEMCCA reprogramming,
approximately 100,000 fibroblast cells were infected overnight with 2–20 ml
of concentrated STEMCCA lentivirus (5 3 10e8 TU/ml) in 1 ml of standard
fibroblast media (DMEM supplemented with 10% FBS, L-glutamine, nones-
sential amino acids, and penicillin-streptomycin) with 5 mg/ml polybrene. Cells
were trypsinized and replated onto 10 cm dishes containing mitomycin-
treated male CF1 mouse embryonic fibroblasts on day 5 postinfection (p.i.)
and media was replaced with standard hESC media (DMEM/F12 supple-
mented with 20% knockout serum replacement, L-glutamine, nonessential
amino acids, penicillin-streptomycin, 2-mercaptoethanol, and 20 ng/ml
bFGF) the next day and changed every day thereafter. hESC-like colonies340 Cell Stem Cell 7, 329–342, September 3, 2010 ª2010 Elsevier Inwere picked between weeks 2 and 3 p.i. and enzymatically passaged with
collagenase IV. Retroviral reprogramming with the MIP vectors (details on
the construct can be found in Supplemental Experimental Procedures) was
performed similarly, except that cells were double infected with 1 ml of uncon-
centrated pMIP retrovirus overnight. Media was supplemented with 1 mg/mL
puromycin on days 3 and 4 p.i. and hESC-like colonies picked between
weeks 3 and 5 p.i. MIP and STEMCCA viruses were produced via standard
procedures. Cytogenetic analysis was performed by Cell Line Genetics
(Madison, WI). hiPSCs were specified toward neural progenitors as described
(Karumbayaram et al., 2009) and teratoma assays were performed by testis
injection according to standard procedures.Immunostaining and FISH
Antibodies used for immunostaining are: H3K27me3 (Upstate 07-449), EZH2
(BD 612666), macroH2A1 (rabbit polyclonal), NANOG (Abcam ab21624),
TRA1-60 (Millipore MAB4360), H4K18ac (kindly provided by the Grunstein
laboratory, UCLA), H3K4me3 (Abcam ab8580), and H4K20me1 (Abcam
ab9051). For immunostaining, cells grown on coverslips were washed in
PBS and fixed for 10 min at room temperature (RT) in 13 PBS containing
4% PFA. Cells were then permeabilized by incubation with 13 PBS containing
0.5% Triton X-100 for 5 min at RT, transferred into 13 PBS with 0.2% Tween-
20 (PBS/Tween), and then incubated for 30 min in blocking buffer (5% goat
serum, 0.2% fish skin gelatin, 0.2% Tween in 13 PBS). Primary antibody incu-
bations were performed for 2 hr at RT in blocking solution, and cells were
washed in three times in PBS/Tween and incubated with Alexa 488, Alexa
546, or Cy5 labeled secondary antibodies in blocking buffer for 30 min. Cells
were then washed with PBS/Tween, stained with DAPI, and mounted in Aqua-
polymount (Polysciences Inc.). When combining FISH and immunostaining,
immunostaining was performed as described above with the addition of
tRNA (Invitrogen) and RNaseOUT (Invitrogen) to blocking buffer. After immu-
nostaining, cells were fixed again with 13PBS/4% PFA and XIST and ATRX
RNA FISH was performed with double-strand DNA probes labeled with FITC
or Cy3 generated with a Bioprime kit (Invitrogen) from a full-length XIST
cDNA construct or BACs for ATRX (RP11-1145J4 and RP11-42M11) accord-
ing to standard procedures. X chromosome paint was performed according
to standard procedures with probes from Cambio. To quantify cells with Xi
enrichment of chromatin marks, XIST RNA, or allelic expression of ATRX, at
least 200 single cells were inspected under the microscope and the pattern
of enrichment determined. In some quantifications, only NANOG- or TRA1-
60-positive cells were considered and cases in which fewer cells were counted
are indicated.Expression Analysis
In order to confirm expression of the deleted or wild-type DMD allele, we used
PCR fragment length polymorphismswith primer sequences specific to detect
the DMD region between exons 43 and 52 (sequences are available from
Dr. van Deutekom; Aartsma-Rus et al., 2003). To identify X-linked SNPs in
NHDF17914 and DMD fibroblasts, several regions of XIST, ATRX, and
PDHA1 were amplified from genomic DNA by PCR, TOPO XL (Invitrogen)
cloned and sequenced. Four regions, each carrying a single SNP that confers
allele-specific differences in restriction enzyme digests, were found within the
coding regions of these three genes (Figure S4). To allow allele-specific
expression analysis, cDNA was generated from RNA of different cell lines via
the First Strand cDNA synthesis (Invitrogen), and SNP-containing regions
were amplified by PCR with primers given in Table S2 and analyzed by restric-
tion digest with Mfe1, Afe1, BseRI, and Pst1, respectively (Figure S4). Similar
cDNA preparations were used in real-time PCR experiments (primers given in
Table S2) to determine transcript levels of pluripotency or virally encoded
genes in triplicate reactions. Global gene expression analysis was performed
as described previously (Chin et al., 2009).Bisulfite Sequencing
Bisulfite conversion of genomic DNA was performed with the EpiTect Bisulfite
Kit (QIAGEN) followed by PCR via HotStarTaq DNA polymerase. Primer
sequences are given in Table S2.c.
Cell Stem Cell
Female Human iPSCs Retain an Inactive X ChromosomeEZH2 RNAi and Overexpression Experiments
siRNAs targeting EZH2 were obtained from Dharmacon. 50 nM of siRNA
were transfected into hiPSCs with Lipofectamine RNAiMax (Invitrogen) as
described by themanufacturer. Cells were fixed and analyzed 72 hr after trans-
fection. For overexpression, EZH2 was cloned into pEGFP-C3 (Clontech),
transfected into primary fibroblasts, and analyzed 48 hr later.
ACCESSION NUMBERS
Data are deposited at NCBI’s Gene Expression Omnibus under accession
number GSE22246.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
doi:10.1016/j.stem.2010.06.024.
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